KURN Kuros Biosciences AG

Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

Kuros Biosciences AG / Key word(s): Annual Results
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update

08.03.2024 / 07:00 CET/CEST

-    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST

Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.  Following the announcement, the company will host a video conference call at 3pm CET/10am US EST to discuss the results. 

To register for the video call, click . 

For further information, please contact:

Kuros Biosciences AG 
Daniel Geiger
Chief Financial Officer
t: 7
e: 		 LifeSci Advisors 
Sandya von der Weid
Investors
t:
e: 

About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic fusion technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across three continents and in 25,000 fusion surgeries. For more information on the company, its products and pipeline, visit .


End of Media Release
Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone:
Fax:
E-mail:
Internet:
ISIN: CH0325814116
Valor: 32581411
Listed: SIX Swiss Exchange
EQS News ID: 1854131

 
End of News EQS News Service

1854131  08.03.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1854131&application_name=news&site_id=research_pool
EN
08/03/2024

Underlying

KURNKuros Biosciences AG

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kuros Biosciences AG

Free Trial
KURN Kuros Bioscienc...

Kuros Biosciences AG: 1 director

A director at Kuros Biosciences AG sold 225,000 shares at 20.900CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

KURN KUROS BIOSCIENCES AG
12/12/24 December 12, 2024 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences Expands into Extremities Markets

Kuros Biosciences AG / Key word(s): Miscellaneous/Personnel Kuros Biosciences Expands into Extremities Markets 19.11.2024 / 07:00 CET/CEST Commercial Highlights Appointment of Jantzen Cole as Vice President of Market Development, Extremities, to drive the Company’s acceleration beyond the spine market  Strategic expansion opens new addressable market opportunity estimated at $1 billion Formation of a dedicated Surgeon Advisory Board to shape clinical and commercial strategies for MagnetOsTM in extremities markets Schlieren (Zurich), Switzerland, November 19, 2024 – Kuros Bioscie...

November 19, 2024 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA...

Kuros Biosciences AG / Key word(s): Study results/Scientific publication Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft 25.06.2024 / 07:00 CET/CEST Schlieren (Zurich), Switzerland, June 25, 2024 – Kuros Biosciences, a leader in next generation bone healing technologies, today announced the publication of a peer-reviewed manuscript that details the clinical data of its MAXA Level 1 prospective, multi-center, randomized, intra-patient controlled clinical study in Spine1.   Published clinica...

June 25, 2024 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Annual General Meeting of Kuros Biosciences approves all resolutions

Kuros Biosciences AG / Key word(s): AGMEGM Annual General Meeting of Kuros Biosciences approves all resolutions 17.04.2024 / 14:05 CET/CEST Schlieren (Zurich), Switzerland, April 17, 2024 – Kuros Biosciences (SIX:KURN), a leader in next generation bone graft technologies, held its Annual General Meeting today.  The Annual General Meeting approved the Annual Report, the Annual Financial Statements, and the Consolidated Financial Statements for the year 2023 and took note of the Reports of the Auditors. Shareholders granted discharge to the Board and the Executive Committee, voted i...

April 17, 2024 1 EN
 PRESS RELEASE
Free
KURN Kuros Bioscienc...

Kuros Biosciences to Report Full Year Financial Results for 2023 and P...

Kuros Biosciences AG / Key word(s): Annual Results Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update 08.03.2024 / 07:00 CET/CEST -    Company to host conference call and webcast on March 13, 2024, at 3pm CET/10am US EST Schlieren (Zurich), Switzerland, March 8, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next-generation bone graft technologies, today announced that it will report its full-year financial results and provide a corporate update on its business on March 13, 2024.  Following the announcement, the company w...

March 8, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch